BVF Inc’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-890,072
| Closed | -$41M | – | 71 |
|
|
2023
Q4 | $41M | Sell |
890,072
-937,886
| -51% | -$33.1M | 1.03% | 25 |
|
|
2023
Q3 | $62.4M | Hold |
1,827,958
| – | – | 1.68% | 16 |
|
|
2023
Q2 | $70.4M | Hold |
1,827,958
| – | – | 1.96% | 15 |
|
|
2023
Q1 | $65.4M | Buy |
1,827,958
+556,715
| +44% | +$20.6M | 2.39% | 14 |
|
|
2022
Q4 | $50.1M | Buy |
1,271,243
+370,148
| +41% | +$13.5M | 2.12% | 14 |
|
|
2022
Q3 | $32.5M | Sell |
901,095
-696,871
| -44% | -$25.1M | 1.34% | 25 |
|
|
2022
Q2 | $48.6M | Hold |
1,597,966
| – | – | 2.35% | 15 |
|
|
2022
Q1 | $48.9M | Sell |
1,597,966
-1,691,574
| -51% | -$50.6M | 1.95% | 16 |
|
|
2021
Q4 | $103M | Buy |
3,289,540
+1,717,762
| +109% | +$51.3M | 3.73% | 6 |
|
|
2021
Q3 | $24M | Hold |
1,571,778
| – | – | 0.94% | 30 |
|
|
2021
Q2 | $29.3M | Sell |
1,571,778
-1,910,000
| -55% | -$35.2M | 1.1% | 24 |
|
|
2021
Q1 | $62.3M | Sell |
3,481,778
-17,568
| -0.5% | -$298K | 2.34% | 12 |
|
|
2020
Q4 | $53.8M | Hold |
3,499,346
| – | – | 2.12% | 13 |
|
|
2020
Q3 | $38.7M | Sell |
3,499,346
-17,505
| -0.5% | -$206K | 2.11% | 19 |
|
|
2020
Q2 | $44.1M | Buy |
3,516,851
+842,513
| +32% | +$10.7M | 2.72% | 15 |
|
|
2020
Q1 | $30.3M | Buy |
2,674,338
+725,263
| +37% | +$10.3M | 2.83% | 12 |
|
|
2019
Q4 | $25.6M | Buy |
1,949,075
+207,475
| +12% | +$2.18M | 1.94% | 16 |
|
|
2019
Q3 | $15.7M | Hold |
1,741,600
| – | – | 1.65% | 20 |
|
|
2019
Q2 | $17.2M | Sell |
1,741,600
-47,174
| -3% | -$451K | 1.88% | 19 |
|
|
2019
Q1 | $18.2M | Hold |
1,788,774
| – | – | 2.04% | 18 |
|
|
2018
Q4 | $11.3M | Buy |
1,788,774
+623,221
| +53% | +$5.54M | 1.48% | 24 |
|
|
2018
Q3 | $15.4M | Buy |
1,165,553
+444,723
| +62% | +$5.15M | 1.35% | 26 |
|
|
2018
Q2 | $6.63M | Hold |
720,830
| – | – | 0.65% | 38 |
|
|
2018
Q1 | $3.53M | Sell |
720,830
-2,868,000
| -80% | -$10.6M | 0.36% | 38 |
|
|
2017
Q4 | $10.1M | Hold |
3,588,830
| – | – | 1.22% | 25 |
|
|
2017
Q3 | $10.6M | Buy |
3,588,830
+70,000
| +2% | +$217K | 1.35% | 23 |
|
|
2017
Q2 | $11.1M | Buy |
3,518,830
+569,036
| +19% | +$2.22M | 1.72% | 19 |
|
|
2017
Q1 | $11.8M | Sell |
2,949,794
-94,011
| -3% | -$739K | 2.01% | 17 |
|
|
2016
Q4 | $23.4M | Sell |
3,043,805
-65,100
| -2% | -$523K | 4.71% | 6 |
|
|
2016
Q3 | $25.2M | Buy |
3,108,905
+1,333,333
| +75% | +$10.3M | 4.75% | 9 |
|
|
2016
Q2 | $10.5M | Hold |
1,775,572
| – | – | 2.24% | 15 |
|
|
2016
Q1 | $12.4M | Buy |
1,775,572
+650,000
| +58% | +$4.67M | 3.07% | 14 |
|
|
2015
Q4 | $9.05M | Buy |
1,125,572
+90,000
| +9% | +$771K | 1.54% | 20 |
|
|
2015
Q3 | $8.55M | Buy |
1,035,572
+356,808
| +53% | +$3.54M | 1.73% | 17 |
|
|
2015
Q2 | $7.83M | Buy |
678,764
+287,340
| +73% | +$3.97M | 1.38% | 20 |
|
|
2015
Q1 | $6.6M | Sell |
391,424
-226,800
| -37% | -$4.19M | 1.38% | 19 |
|
|
2014
Q4 | $12.2M | Buy |
+618,224
| New | +$9.08M | 2.38% | 15 |
|
Other funds holding XENE
ACA
DCM
PCH
PBA
CC
BVF Inc's XENE Position: Q1 2024 in Review
BVF Inc sold out of Xenon Pharmaceuticals (XENE) in Q1 2024, closing a stake of 890,072 shares — an estimated $41M sold.
BVF Inc first reported a position in XENE in Q4 2014 and held it in 37 quarters. The position peaked at $103M in Q4 2021. 220 funds tracked by Wall St. Rank hold XENE as of Q1 2024.
- BVF Inc reported no remaining Xenon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
- BVF Inc sold 890,072 Xenon Pharmaceuticals shares in Q1 2024, an estimated $41M.
- BVF Inc first reported a position in Xenon Pharmaceuticals in Q4 2014 and held it in 37 quarters.
- BVF Inc's Xenon Pharmaceuticals position peaked at $103M in Q4 2021.
- 220 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2024.
Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.